Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Sr. Manager, Pharma and Biotech Segment
Connect with Nicki Catchpole on LinkedIn
Follow Nicki Catchpole on Twitter
About the author:
As a professional with over 14 years of experience in strategy development and partnership management across a variety of industries, Nicki’s latest role as a Senior Manager, Segment Marketing at Elsevier applies her skills to the area of drug discovery and development in the Pharma and Biotech industry.
In this capacity she is focused on understanding biopharmaceutical R&D challenges and turning them into opportunity to further Elsevier’s ability to serve industry executives and the professionals who innovate in the drug discovery and development space. Prior to joining Elsevier, Nicki held senior alliance and strategy roles in the Legal, Tax & Accounting, Life Sciences and Cyber Security industries.
Nicki resides in New York City and holds a BA in English Literature and Mandarin Chinese from Carleton College in Northfield, MN.
Posts by Nicki Catchpole
Posted on May 1st, 2019 in Pharma R&D
Elsevier’s Tim Miller’s article in World Pharma Today provides a insightful lens into the reality behind the complexities of implementing artificial intelligence into the R&D cycle. While great strides have been made, the runway to realize the potential is a long one and there are many exciting discoveries left to be made and obstacles to overcome.(more…)
Posted on April 25th, 2019 in Pharma R&D
Today marks the WHO’s worldwide recognition of those affected by malaria and the widespread global effort to develop a cure. The Elsevier Professional Services team exemplifies this effort with the creation of a database covering interactions and functions of P. faciparum proteins. This is the deadliest of the Plasmodium species that cause malaria in human beings.(more…)
Posted on April 23rd, 2019 in Pharma R&D
Elsevier’s Maria Shkrob’s study takes an microscopic lens to the topic of how data mapping and analytics can exposure the “under the radar” effects and potential dangers of inactive ingredients in drugs.(more…)
Posted on April 16th, 2019 in Pharma R&D
Go to any conference these days and the number one buzzword is AI. However, despite all the excitement, AI is still talked about in fairly vague terms – with few people able to pin down exactly what they mean by AI. New research from some of my Elsevier colleagues examined this phenomenon.(more…)